LymphoStat-B fails lupus Phase II

HGSI was off $4.10 (29%) to $9.87 on 49.6 million shares on Wednesday on news that its LymphoStat-B belimumab missed the primary endpoints in a Phase II trial to treat systemic lupus erythematosus (SL...